HT
NBIX icon

Heritage Trust’s Neurocrine Biosciences NBIX Stock Holding History

Heritage Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,815
Closed -$663K – 244
2021
Q2 		$663K Sell
6,815
-1,090
-14% -$104K 0.09% 159
2021
Q1 		$769K Buy
7,905
+140
+2% +$14.7K 0.12% 144
2020
Q4 		$744K Buy
7,765
+5
+0.1% +$483 0.12% 138
2020
Q3 		$746K Buy
7,760
+280
+4% +$32.4K 0.14% 124
2020
Q2 		$913K Buy
+7,480
New +$827K 0.18% 114
2019
Q1 		– Sell
-212
Closed -$15K – 329
2018
Q4 		$15K Buy
212
+112
+112% +$10.7K 0.01% 279
2018
Q3 		$12K Buy
100
+42
+72% +$4.76K ﹤0.01% 304
2018
Q2 		$6K Buy
+58
New +$5.19K ﹤0.01% 339

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Heritage Trust's NBIX Position: Q3 2021 in Review

Heritage Trust sold out of Neurocrine Biosciences (NBIX) in Q3 2021, closing a stake of 6,815 shares — an estimated $663K sold.

Heritage Trust first reported a position in NBIX in Q2 2018 and held it in 8 quarters. The position peaked at $913K in Q2 2020. 396 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

  • Heritage Trust reported no remaining Neurocrine Biosciences position as of Q3 2021 after selling out during the quarter.
  • Heritage Trust sold 6,815 Neurocrine Biosciences shares in Q3 2021, an estimated $663K.
  • Heritage Trust first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 8 quarters.
  • Heritage Trust's Neurocrine Biosciences position peaked at $913K in Q2 2020.
  • 396 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on Heritage Trust's 13F filing for Q3 2021, filed 9 Nov 2021.